Comparing short and long antibiotic treatments for bloodstream infections caused by Streptococcus pneumoniae
Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream
This study is testing whether shorter or longer antibiotic treatments are better for adults with bloodstream infections caused by Streptococcus pneumoniae.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Methodist Health System Academic / other |
| Locations | 1 site (Dallas, Texas) |
| Trial ID | NCT06096025 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness and safety of short versus long durations of antibiotic therapy for bloodstream infections caused by Streptococcus pneumoniae. It focuses on patients aged 18 and older who have tested positive for S. pneumoniae in blood cultures and have started intravenous antibiotic treatment within 48 hours. The study will analyze clinical outcomes based on treatment duration, addressing a gap in current guidelines regarding optimal therapy length for this common pathogen. By comparing treatment durations, the study seeks to provide clearer recommendations for managing these infections.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with confirmed S. pneumoniae bacteremia who are clinically stable by day 10 of therapy.
Not a fit: Patients with polymicrobial bloodstream infections or those requiring invasive interventions for S. pneumoniae may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective treatment protocols for patients with bloodstream infections, potentially reducing morbidity and healthcare costs.
How similar studies have performed: While there is limited data specifically on S. pneumoniae, other studies have shown success in evaluating treatment durations for different pathogens, indicating potential for meaningful insights in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * • ≥18 years of age * S. pneumoniae isolated from ≥1 blood cultures * Active IV antibiotic therapy within 48 hours of the first positive blood culture(7,8) * Clinical stability by day 10 of therapy Exclusion Criteria: * • Treatment duration \<5 days or \>16 days * Death before completion of therapy (\<10 days vs. ≥ 10 days ) * Polymicrobial BSI * Invasive infection caused by S. pneumoniae (endocarditis, meningitis, and lung abscess)
Where this trial is running
Dallas, Texas
- Methodist Dallas Medical Center — Dallas, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Matthew Crotty, PharmD — Methodist Midlothian Medical Center
- Study coordinator: Bethany Brauer, MPH
- Email: MHSIRB@mhd.com
- Phone: 214-947-4681
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.